Literature DB >> 35863783

MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of BRAF V600E Mutation, BRAF Fusion, and Wild-Type Tumors in Patients without Neurofibromatosis-1.

A Trasolini1,2, C Erker1,3, S Cheng4, C Crowell1,5, K McFadden1,6, R Moineddin7, M A Sargent8, D Mata-Mbemba9,10,11.   

Abstract

BACKGROUND AND
PURPOSE: The prognosis and treatment of pediatric low-grade gliomas is influenced by their molecular subtype. MR imaging remains the mainstay for initial work-up and surgical planning. We aimed to determine the relationship between imaging patterns and molecular subtypes of pediatric low-grade gliomas.
MATERIALS AND METHODS: This was a retrospective bi-institutional study for patients diagnosed from 2004 to 2021 with pathologically confirmed pediatric low-grade gliomas molecularly defined as BRAF fusion, BRAF V600E mutant, or wild-type (which is neither BRAF V600E mutant nor BRAF fusion). Two neuroradiologists, blinded, independently reviewed imaging parameters from diagnostic MRIs, and discrepancies were resolved by consensus. Bivariate analysis was used followed by pair-wise comparison of the Dwass-Steel-Critchlow-Fligner method to compare the 3 molecular subtypes. Interreader agreement was assessed using κ.
RESULTS: We included 70 patients: 30 BRAF fusion, 19 BRAF V600E mutant, and 21 wild-type. There was substantial agreement between the readers for overall imaging variables (κ = 0.75). BRAF fusion tumors compared with BRAF V600E and wild-type tumors were larger (P = .0022), and had a greater mass effect (P = .0053), increased frequency of hydrocephalus (P = .0002), and diffuse enhancement (p <.0001). BRAF V600E mutant tumors were more often hemispheric (P < .0001), appeared more infiltrative (P = .0002), and, though infrequent, were the only group demonstrating diffusion restriction (qualitatively; P = .0042) with a lower ADC ratio (quantitatively) (P = .003).
CONCLUSIONS: BRAF fusion and BRAF V600E mutant pediatric low-grade gliomas have unique imaging features that can be used to differentiate them from each other and wild-type pediatric low-grade glioma using a standard radiology review with high interreader agreement. In the era of targeted therapy, these features can be useful for therapeutic planning before surgery.
© 2022 by American Journal of Neuroradiology.

Entities:  

Year:  2022        PMID: 35863783      PMCID: PMC9575425          DOI: 10.3174/ajnr.A7574

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   4.966


  26 in total

1.  MR Imaging Characteristics of Wingless-Type-Subgroup Pediatric Medulloblastoma.

Authors:  Z Patay; L A DeSain; S N Hwang; A Coan; Y Li; D W Ellison
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-03       Impact factor: 3.825

Review 2.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors:  Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-10-01       Impact factor: 12.300

3.  Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Authors:  Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Anuradha Banerjee; Roger J Packer; Lindsay B Kilburn; Stewart Goldman; Ian F Pollack; Ibrahim Qaddoumi; Regina I Jakacki; Paul G Fisher; Girish Dhall; Patricia Baxter; Susan G Kreissman; Clinton F Stewart; David T W Jones; Stefan M Pfister; Gilbert Vezina; Jessica S Stern; Ashok Panigrahy; Zoltan Patay; Benita Tamrazi; Jeremy Y Jones; Sofia S Haque; David S Enterline; Soonmee Cha; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi
Journal:  Lancet Oncol       Date:  2019-05-28       Impact factor: 41.316

4.  A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702).

Authors:  Tore Stokland; Jo-Fen Liu; James W Ironside; David W Ellison; Roger Taylor; Kathryn J Robinson; Susan V Picton; David A Walker
Journal:  Neuro Oncol       Date:  2010-09-22       Impact factor: 12.300

5.  Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jill M Hagenkord; Ronald L Hamilton; Ian F Pollack
Journal:  Neuro Oncol       Date:  2012-04-05       Impact factor: 12.300

Review 6.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

7.  Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.

Authors:  Liana Nobre; Michal Zapotocky; Vijay Ramaswamy; Scott Ryall; Julie Bennett; Daniel Alderete; Julia Balaguer Guill; Lorena Baroni; Ute Bartels; Abhishek Bavle; Miriam Bornhorst; Daniel R Boue; Adela Canete; Murali Chintagumpala; Scott L Coven; Ofelia Cruz; Sonika Dahiya; Peter Dirks; Ira J Dunkel; David Eisenstat; Cecile Faure Conter; Elizabeth Finch; Jonathan L Finlay; Didier Frappaz; Maria Luisa Garre; Karen Gauvain; Anne Grete Bechensteen; Jordan R Hansford; Inga Harting; Peter Hauser; Lili-Naz Hazrati; Annie Huang; Sarah G Injac; Valentina Iurilli; Matthias Karajannis; Gurcharanjeet Kaur; Martin Kyncl; Lenka Krskova; Normand Laperriere; Valerie Larouche; Alvaro Lassaletta; Sarah Leary; Frank Lin; Samantha Mascelli; Tara McKeown; Till Milde; Andres Morales La Madrid; Giovanni Morana; Helena Morse; Naureen Mushtaq; Diana S Osorio; Roger Packer; Zdenek Pavelka; Eduardo Quiroga-Cantero; James Rutka; Magnus Sabel; Duarte Salgado; Palma Solano; Jaroslav Sterba; Jack Su; David Sumerauer; Michael D Taylor; Helen Toledano; Derek S Tsang; Mariana Valente Fernandes; Frank van Landeghem; Cornelis M van Tilburg; Bev Wilson; Olaf Witt; Josef Zamecnik; Eric Bouffet; Cynthia Hawkins; Uri Tabori
Journal:  JCO Precis Oncol       Date:  2020-05-20

8.  A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.

Authors:  Cheng-Ying Ho; Bret C Mobley; Heather Gordish-Dressman; Christopher J VandenBussche; Gary E Mason; Miriam Bornhorst; Adam J Esbenshade; Mahtab Tehrani; Brent A Orr; Delecia R LaFrance; Joseph M Devaney; Beatrix W Meltzer; Sean E Hofherr; Peter C Burger; Roger J Packer; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2015-08-12       Impact factor: 17.088

9.  Correlation between magnetic resonance imaging characteristics and BRAF alteration status in individuals with optic pathway/hypothalamic pilocytic astrocytomas.

Authors:  Yukitomo Ishi; Shigeru Yamaguchi; Michiharu Yoshida; Hiroaki Motegi; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin
Journal:  J Neuroradiol       Date:  2019-06-20       Impact factor: 3.447

10.  Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells.

Authors:  Zachary J Reitman; Brenton R Paolella; Guillaume Bergthold; Kristine Pelton; Sarah Becker; Robert Jones; Claire E Sinai; Hayley Malkin; Ying Huang; Leslie Grimmet; Zachary T Herbert; Yu Sun; Jessica L Weatherbee; John A Alberta; John F Daley; Orit Rozenblatt-Rosen; Alexandra L Condurat; Kenin Qian; Prasidda Khadka; Rosalind A Segal; Daphne Haas-Kogan; Mariella G Filbin; Mario L Suva; Aviv Regev; Charles D Stiles; Mark W Kieran; Liliana Goumnerova; Keith L Ligon; Alex K Shalek; Pratiti Bandopadhayay; Rameen Beroukhim
Journal:  Nat Commun       Date:  2019-08-19       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.